Sage Therapeutics Inc Revenue Growth Rates (SAGE), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Sage Therapeutics Inc   (NASDAQ: SAGE)
 

SAGE's Revenue Growth by Quarter and Year

Sage Therapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

SAGE Revenue (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter December -
3rd Quarter September -
2nd Quarter June 31.66
1st Quarter March 14.06
FY 45.72

SAGEs Annual Revenue
Sage Therapeutics Inc 's Revenue in the fiscal year 2024 $ 41.24 millions
Sage Therapeutics Inc 's Revenue in the fiscal year 2023 $ 86.46 millions
Sage Therapeutics Inc 's Revenue in the fiscal year 2022 $ 7.69 millions
Sage Therapeutics Inc 's Revenue in the fiscal year 2021 $ 6.31 millions
Sage Therapeutics Inc 's Revenue in the fiscal year 2020 $ 1,114.20 millions




SAGE Revenue second quarter 2025 Y/Y Growth Comment
Sage Therapeutics Inc reported Revenue surge of 266.01% year on year in the second quarter 2025, to $ 31.66 millions, this is lower than Sage Therapeutics Inc 's recent average Revenue surge of 2329.36%.

Looking into second quarter 2025 results within Major Pharmaceutical Preparations industry 20 other companies have achieved higher Revenue growth. While Sage Therapeutics Inc ' s Revenue doubling of 266.01% ranks overall at the positon no. 85 in the second quarter 2025.


SAGE Revenue ( Y/Y Growth %) 2025
 2024 2023 2022
4th Quarter December - -83.56 % 2626.22 % 74.39 %
3rd Quarter September - 336.4 % 56.32 % 20.83 %
2nd Quarter June 266.01 % 250.2 % 64.67 % -8.54 %
1st Quarter March 77.97 % 140.12 % 108.23 % 0 %
FY   - -52.3 % 1025.65 % -

Financial Statements
Sage Therapeutics Inc 's second quarter 2025 Revenue $ 31.66 millions SAGE's Income Statement
Sage Therapeutics Inc 's second quarter 2024 Revenue $ 8.65 millions Quarterly SAGE's Income Statement


SAGE Revenue (Quarter on Quarter Growth %)

 2025
 2024 2023 2022
4th Quarter December - 8 % 2766.54 % 64.37 %
3rd Quarter September - 37.23 % 10.12 % 16 %
2nd Quarter June 125.18 % 9.49 % -24.92 % -5.06 %
1st Quarter March 9.67 % -89.87 % 15.03 % -3.66 %
FY (Year on Year)   - -52.3 % 1025.65 % -


Back to SAGE Growth rate Comparisons >> Back to SAGE Growth rate Comparisons >>


Revenue second quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #21
Healthcare Sector #35
Overall #85

Revenue Y/Y Growth Statistics
High Average Low
56491.12 % 2329.36 % -100 %
(Dec 31 2020)   (Jun 30 2022)
Revenue second quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #21
Healthcare Sector #35
Overall #85
Revenue Y/Y Growth Statistics
High Average Low
56491.12 % 2329.36 % -100 %
(Dec 31 2020)   (Jun 30 2022)

Revenue by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Sage Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
67574.56 % 2436.9 % -100 %
(Dec 31 2020)  


SAGE's II. Quarter Q/Q Revenue Comment
Sage Therapeutics Inc achieved in the II. Quarter 2025 below company average Revenue doubling of 125.18% quarter on quarter, to $ 31.66 millions.

Although the II. Quarter 2025 Revenue Q/Q growth was lower than the regular , this has been yet encouraging story, as the II. Quarter surge, eclipses the 9.49% growth in the II. Quarter a year ago

Within Major Pharmaceutical Preparations industry 19 other companies have achieved higher Revenue quarter on quarter growth. While Sage Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 103.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #20
Healthcare Sector #30
Overall #103
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #20
Healthcare Sector #30
Overall #103
Revenue Q/Q Growth Statistics
High Average Low
67574.56 % 2436.9 % -100 %
(Dec 31 2020)  


SAGE's II. Quarter Q/Q Revenue Comment
Sage Therapeutics Inc achieved in the II. Quarter 2025 below company average Revenue doubling of 125.18% quarter on quarter, to $ 31.66 millions.

II. Quarter 2025 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 9.49% in the II. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 19 other companies have achieved higher Revenue quarter on quarter growth. While Sage Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 103.


Sage Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2025)		 12 Months Ending
(Mar 31 2025)		 12 Months Ending
(Dec 31 2024)		 12 Months Ending
(Sep 30 2024)		 12 Months Ending
(Jun 30 2024)
Cumulative Revenue 12 Months Ending $ 70.41 $ 47.40 $ 41.24 $ 106.40 $ 97.24
Y / Y Revenue Growth (TTM) -27.59 % -47.94 % -52.3 % 837.59 % 837.64 %
Year on Year Revenue Growth Overall Ranking # 19 # 1 # 4 # 24 # 244
Seqeuential Revenue Change (TTM) 48.53 % 14.94 % -61.24 % 9.41 % 6.79 %
Seq. Revenue Growth (TTM) Overall Ranking # 1446 # 588 # 4 # 263 # 562


Cumulative Revenue growth Comment
Sage Therapeutics Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Mar 31 2025. If the fiscal year would end in Jun 30 2025, Sage Therapeutics Inc 's annual Revenue improvement would be -27.59% year on year to $70 millions.

Among companies within the Healthcare sector 7 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1 to 19.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 80
Healthcare Sector # 8
Overall # 19

Revenue TTM Y/Y Growth Statistics
High Average Low
16123.06 %
 3024.52 %
-99.45 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 80
Sector # 248
S&P 500 # 1446
Cumulative Revenue growth Comment
Sage Therapeutics Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Mar 31 2025. If the fiscal year would end in Jun 30 2025, Sage Therapeutics Inc 's annual Revenue drop would be -27.59% year on year to $70 millions.

Among companies within the Healthcare sector 7 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1 to 19.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 80
Healthcare Sector # 8
Overall # 19

Revenue TTM Y/Y Growth Statistics
High Average Low
16123.06 %
3024.52 %
-99.45 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 80
Sector # 248
S&P 500 # 1446




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
SAGE's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Jun 30 2025 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2025
Clearside Biomedical Inc 446.67%$ 446.667 millions
Phathom Pharmaceuticals Inc 439.36%$ 439.364 millions
Invivyd Inc 420.58%$ 420.583 millions
Insight Molecular Diagnostics Inc 398.08%$ 398.077 millions
Monte Rosa Therapeutics Inc 394.01%$ 394.015 millions
Bioadaptives Inc 376.89%$ 376.889 millions
Ascendis Pharma A362.52%$ 362.516 millions
Pluri Inc 314.58%$ 314.583 millions
Day One Biopharmaceuticals Inc 313.92%$ 313.916 millions
Arcus Biosciences Inc 310.26%$ 310.256 millions
Nuvation Bio Inc 291.27%$ 291.268 millions
Siga Technologies Inc271.92%$ 271.924 millions
Sage Therapeutics Inc 265.84%$ 265.842 millions
X4 Pharmaceuticals Inc250.44%$ 250.444 millions
Xilio Therapeutics Inc 242.98%$ 242.978 millions
Biorestorative Therapies Inc 240.40%$ 240.404 millions
Keros Therapeutics Inc 235.51%$ 235.512 millions
Ethema Health Corporation 229.20%$ 229.201 millions
Sol gel Technologies Ltd 217.71%$ 217.707 millions
Delcath Systems Inc 211.05%$ 211.048 millions
Picard Medical Inc 207.06%$ 207.061 millions
4d Molecular Therapeutics Inc 200.00%$ 200.000 millions
Astrotech Corp197.30%$ 197.297 millions
Vistagen Therapeutics Inc 190.48%$ 190.476 millions
Stoke Therapeutics Inc 186.01%$ 186.007 millions
Geovax Labs Inc 183.45%$ 183.454 millions
Rigel Pharmaceuticals Inc176.01%$ 176.010 millions
Quoin Pharmaceuticals Ltd 175.79%$ 175.792 millions
Arcutis Biotherapeutics Inc 164.13%$ 164.126 millions
Ataibeckley Inc 163.37%$ 163.370 millions


About Sage Therapeutics Inc Revenue Growth Rates (SAGE), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Sage Therapeutics Inc (CIK 1597553).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0000950170-25-100276
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Sage Therapeutics Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.